Laryngeal carcinoma (LC) remains a challenging malignancy with poor prognosis, necessitating the identification of novel therapeutic targets. This study investigates the functional role and underlying mechanism of the extracellular matrix protein Laminin Subunit Beta-3 (LAMB3) in LC progression. Bioinformatics analysis...

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous malignancy, with 50–80% of cases exhibiting elevated EGFR expression. Dysregulated endocytic trafficking contributes to sustained receptor signaling and tumor progression, suggesting endocytosis as a potential therapeutic target. Transcriptome analysis of paired...

BackgroundComparative evidence regarding the efficacy and safety of almonertinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cance Abstract Background: Comparative evidence regarding the efficacy and safety of almonertinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer...

Lantern Pharma Inc., a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration...

--ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung...